Home / PSMA

PSMA

July 12, 2023

Non-FDG PET tracers in oncology: the story so far

The role of radionuclide molecular imaging in oncology with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG) is well established. There is ample evidence to support the role of 18F-FDG PETCT in various clinical scenarios and cancer types. However, there has been a phenomenal expansion in non-FDG PET radiopharmaceuticals for use in clinical oncology. 68Ga is a well established radionuclide […]

Dr Gopinath Gnanasegaran

Royal Free London NHS Foundation Trust

Read Article

December 15, 2021

PSMA diagnostics and therapy

Prostate cancer is now the most commonly diagnosed non-cutaneous malignancy in the UK, accounting for over 40,000 new diagnoses and 11,000 deaths annually. It is estimated that more than 400,000 men are currently living with the disease. Recent years have seen massive improvements in the understanding and treatment of prostate cancer, in particular the treatment […]